Theratechnologies Inc
Company Information

2015 Rue Peel 5eme Etage
Montréal, QC, H3A 1T8 Canada
(514) 336-7800

Theratechnologies Inc Rankings

TSX Smallcap

Top 3 Competitors

Unlock more access to Hoover’s!

  • Build customized email lists 24/7, based on your best customer profile.
  • Learn more about the companies you want to sell to. Hoover’s has reports on 85+ million companies and 900 industries. 65,000 data points are updated each day.
  • Get real insight written by real people – exclusive research and reviews by our in-house Editorial staff.
  • We can deliver our data to your desktop, to Excel, direct to your CRM, into your custom app, or via mobile.

Call (866) 473-3932 today to get started with a FREE TRIAL!


Theratechnologies Inc Company Profile

Theratechnologies is pepped up on peptides. The Canadian company develops peptide sequences to treat endocrine and metabolic conditions such as growth hormone deficiencies. Lead drug EGRIFTA (tesamorelin for injection) is being marketed for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Theratechnologies received US approval for EGRIFTS in 2010 and approval in Canada and Mexico in 2015. The drug is marketed solely in the US (in partnership with inVentiv Health) and Canada. It is seeking to market EGRIFTA elsewhere around the world through partnerships with Sanofi, AOP Orphan Pharmaceuticals, and BL&H Co.